|
Originally published In Press as doi:10.1074/jbc.M206556200 on September 16, 2002
J. Biol. Chem., Vol. 277, Issue 47, 45510-45517, November 22, 2002
Functional Analysis of the TFIID-specific Yeast TAF4
(yTAFII48) Reveals an Unexpected Organization of Its
Histone-fold Domain*
Sylvie
Thuault §,
Yann-Gaël
Gangloff ¶ ,
Jay
Kirchner**,
Steven
Sanders**,
Sebastiaan
Werten ,
Christophe
Romier ,
P. Anthony
Weil**, and
Irwin
Davidson 
From the Institut de Génétique et de
Biologie Moléculaire et Cellulaire,
CNRS/INSERM/Université Louis Pasteur,
Boîte Postale 163-67404 Illkirch Cédex, Communauté
Urbaine de Strasbourg, France, and the ** Department
of Molecular Physiology and Biophysics, Vanderbilt University School of
Medecine, Nashville, Tennessee 37232-0615
Received for publication, July 2, 2002, and in revised form, September 4, 2002
 |
ABSTRACT |
Yeast TFIID comprises the TATA binding
protein and 14 TBP-associated factors
(TAFIIs), nine of which contain
histone-fold domains (HFDs). The C-terminal region of the
TFIID-specific yTAF4 (yTAFII48) containing the HFD
shares strong sequence similarity with Drosophila
(d)TAF4 (dTAFII110) and human TAF4 (hTAFII135). A structure/function analysis of yTAF4 demonstrates that the HFD, a
short conserved C-terminal domain (CCTD), and the region separating them are all required for yTAF4 function. Temperature-sensitive mutations in the yTAF4 HFD 2 helix or the CCTD can be suppressed upon overexpression of yTAF12 (yTAFII68). Moreover,
coexpression in Escherichia coli indicates direct
yTAF4-yTAF12 heterodimerization optimally requires both the yTAF4 HFD
and CCTD. The x-ray crystal structure of the orthologous hTAF4-hTAF12
histone-like heterodimer indicates that the 3 region within the
predicted TAF4 HFD is unstructured and does not correspond to the
bona fide 3 helix. Our functional and biochemical
analysis of yTAF4, rather provides strong evidence that the HFD 3
helix of the TAF4 family lies within the CCTD. These results reveal an
unexpected and novel HFD organization in which the 3 helix is
separated from the 2 helix by an extended loop containing a
conserved functional domain.
 |
INTRODUCTION |
Accurate transcription initiation at protein-coding genes by RNA
polymerase II requires the assembly of a multiprotein complex around the mRNA start site (1). Transcription factor TFIID is one
of the general factors involved in this process. TFIID comprises the
TATA binding protein (TBP),1
responsible for specific binding to the TATA element found in many RNA
polymerase II promoters, and a set of TBP-associated factors
(TAFIIs) (2, 3). A subset of TAFIIs are
present not only in TFIID but also in the SAGA, PCAF,
STAGA, and TFTC complexes that lack TBP but are involved in RNA
polymerase II transcription (4-8). A subset of TAFIIs are
also found in a macromolecular complex containing Drosophila
polycomb group proteins (9).
The function of TAFIIs has been studied in several
organisms. In yeast, the genes encoding all of the TFIID components,
with the exception of yTAF14, are essential for viability. Genetic studies have shown that TAFIIs play an important role in
transcriptional regulation of many genes (10). Temperature-sensitive
(TS) mutations in yTAF1 and yTAF5 provoke cell cycle arrest where the
expression of only a small number of genes is affected (11, 12). In
contrast, TS mutations in yTAF6, yTAF9, yTAF10, and yTAF12 or
the TFIID-specific yTAF11 lead to a dramatic decrease in overall
transcription levels (13-18). Studies in Drosophila have
shown that TAFIIs are involved in the transcriptional
regulation of genes during development (19-22). In mammalian cells,
TAFIIs again seem to be involved in cell cycle control and
are essential for the viability of proliferating cells (23-26).
The histone-fold domain (HFD) plays an important role in the structural
organization of TFIID. Sequence comparisons and structural studies
indicated that TAF6 and TAF9 contain HFDs similar to those of core
histones H4 and H3, which interact to form an H3-H4-like heterotetramer
(27, 28). hTAF4 and hTAF12 heterodimerize via HFDs similar to those of
H2A and H2B, respectively (29). It has been suggested that the
TAF6-TAF9 heterotetramer may associate with the TAF4-TAF12 heterodimer
to form an octameric substructure within TFIID (28, 29). The equivalent
yTAFIIs have been shown to assemble in vitro to
form a macromolecular complex with stoichiometry (yTAF6-yTAF9)2-2(yTAF4-yTAF12) consistent with that of a
histone-like octamer (30). The possible existence of such a structure
in vivo is supported by high copy suppressor genetic
interactions in yeast (15, 30) and the finding that these four
yTAFIIs colocalize within the same subdomain of native
yeast TFIID (31).
X-ray crystallography has shown that hTAF11 and hTAF13 heterodimerize
via HFDs, and this interaction is in agreement with a corresponding
in vivo genetic interaction between their yeast orthologues
(14, 32). Biochemical studies have also indicated that yTAF3 and yTAF8
contain HFDs that heterodimerize with a HFD in yTAF10 (33). A similar
result was obtained in studies of their metazoan orthologues (21, 34).
The existence of these heterodimers in native yeast TFIID is supported
by immunoelectron microscopy, which shows colocalization of these
proteins (31). Hence, nine yTAFIIs contain HFDs that
specifically heterodimerize to form five histone-like pairs (for
review, see Ref. 3).
TSG2/yTAF4 shows significant sequence similarity to the metazoan TAF4
and TAF4b proteins (35, 36). Overexpression of yTAF4 suppresses the TS
phenotype of a mutation in yTAF12, and these TAFIIs
interact physically with one another (30, 35), although the precise
domains required for their interaction have not been described.
Although the yTAF4 HFD shows sequence similarity to those of its
metazoan counterparts, additional shared regions of similarity exist in
the C terminus. To better understand the function of each region and
their contribution to heterodimerization with yTAF12, we have made a
detailed structure-function analysis of yTAF4. We show that the HFD is
essential, but not sufficient, for yTAF4 function, which additionally
requires the short highly conserved C-terminal domain (CCTD) and the
intervening linker region. We demonstrate a strong genetic interaction
between the yTAF4 CCTD and yTAF12 in vivo, and coexpression
in Escherichia coli shows that the CCTD also contributes to
direct yTAF4-yTAF12 heterodimerization in vitro. Together
with the structure of the orthologous hTAF4-hTAF12 heterodimer (48),
our results provide evidence that the 3 helix of the TAF4 HFD is
located within the CCTD and reveal a novel HFD organization in which
the 2 helix is separated from the 3 helix by an extended L2 loop
containing a functional domain.
 |
EXPERIMENTAL PROCEDURES |
Yeast Strains--
The yeast strains used in this study are:
YSLS46 (MATa leu2 0 ura3 0 his3 1 met15 0
KAN taf4 [pRS416ADH-TAF4]), used for plasmid shuffling of
TAF4, was derived from YSLS40 (36) by sporulation and tetrad
dissection; YSLS46/4 (MATa leu2 0 ura3 0 his3 1
met15 0 KAN taf4 [pAS3-TAF4]); YSLS46/4m4 (MATa leu2 0 ura3 0 his3 1 met15 0
KAN taf4 [pAS3-TAF4(M219P)]); YSLS46/4 (186-388)
(MATa leu2 0 ura3 0 his3 1 met15 0
KAN taf4 [pAS3-TAF4 (186-388)]); and YSLS46/4m5
(MATa leu2 0 ura3 0 his3 1 met15 0
KAN taf4 [pAS3-TAF4 (186-388)(R362A, D363A)]).
Construction of Recombinant Plasmids--
All yeast
and bacterial expression vectors were constructed by PCR using
oligonucleotide primers with the appropriate restriction sites (details
available on request). All constructs were verified by restriction
enzyme analysis and automated sequencing. For complementation experiments, wild-type or mutated TAFIIs were cloned in
pAS3 with a Leu marker as previously described (33). A low copy
expression plasmid containing the native yTAF4 promoter was constructed
by introducing a cassette comprising 500 bp of sequence upstream of the
yTAF4 ATG into the pRS415 vector (37) (pRS415taf4p). Downstream of the
ATG, a sequence encoding the FLAG epitope was inserted followed by
restriction sites allowing the in-frame cloning of the wild-type or
mutated yTAF4 derivatives.
Yeast Complementation Assays and High-copy-number
Temperature-sensitive Suppression Assays--
All strains were
transformed by the LiAc technique. For complementation assays, the
indicated plasmids were transformed and the wild-type yTAF4 URA3
plasmid was shuffled out by two passes on media containing
5-fluororotic acid as previously described (33). For suppression
of the yTAF4 mutant strains, cells were transformed with
high-copy-number vectors with URA3 or HIS3 markers expressing the
indicated yTAFII. Transformed yeast were then grown at the
indicated temperatures. In all experiments, cultures were grown in
yeast extract-peptone dextrose medium. Auxotrophic selections were performed in the appropriate synthetic dextrose medium.
RNA Isolation and Quantitation of Poly(A)+
RNA--
Total RNA was isolated from strains grown at the indicated
temperatures for the indicated times as described above. In each case
the cultures were immediately cooled, pelleted for 5 min at 4000 rpm,
washed twice in cold H2O, repelleted, and frozen at
80 °C. Total RNA was isolated by the hot phenol/chloroform method
and subsequently quantified (38). Analysis of poly(A)+ RNA
was performed on slot blots by hybridization with an oligo(dT) probe
and quantified by Phosphorimager analysis (Amersham Biosciences) as previously described (18). All samples were analyzed in triplicate, and the average values ± standard error are shown.
Coexpression in E. coli--
Coexpression in
E. coli was performed as previously described (29). The
derivative of yTAF12 was expressed as a histidine-tagged fusion protein
in pET-15b. Native untagged derivatives of yTAF4 were expressed from a
modified version of the vector pACYC184 (PerkinElmer Life Sciences)
(39).
 |
RESULTS |
Evolutionarily Conserved Regions of yTAF4 Are Required for Function
in Vivo--
Comparison of the amino acid sequence of yTAF4 to
those of its metazoan orthologues hTAF4, dTAF4, and hTAF4b indicates
strong similarity in the C-terminal domain of the proteins. This
region can be divided into three sub-domains, the HFD, a short strongly conserved domain at the extreme C terminus (Conserved C-Terminal Domain, CCTD), and an intervening linker region (Fig.
1). To address the requirement of these
domains for function in vivo, a set of deletion mutants were
constructed (Fig. 2A) and
tested for their ability to rescue the growth of the yeast
taf4 null strain.

View larger version (41K):
[in this window]
[in a new window]
|
Fig. 1.
Sequence comparison of yTAF4 with its
metazoan orthologues. The sequence of yTAF4 is compared with that
of hTAF4, hTAF4b, and dTAF4. Highly conserved positions are shown in
white against a black background and additional
residues conserved among at least three of the family members (mostly
the metazoan homologues) are boxed in light blue. Amino
acids were classified as follows: small residues, P, A, G, S, T;
hydrophobic, L, I, V, A, F, M, C, Y, W; polar/acidic, D, E, Q, N;
basic, R, K, H. Threonine residues are occasionally present in
otherwise hydrophobic positions. The locations of -helices 1 and 2 are based on the known crystal structure where the 2 helix seen in
the crystal is shown by the dark blue box and its expected
length is indicated by the light blue box. The previously
proposed 3 helix and the L1 and L2 loops within the HFD are
indicated along with the CCTD. B, the sequence homology
between the CCTD and other experimentally determined 3 helices dTAF6
and dTAF9 (along with their human and yeast orthologues) and NFY B and
C is indicated. The conserved D(L/V/M/I) pair is shown in
white against a black background along with other
highly conserved hydrophobic positions. Positions where there are
predominantly conserved charged or polar residues are shown with
blue shading. The asterisks indicate amino acids
mutated in yTAF4m5 described here or in Selleck et al. (30),
whose TS phenotype can be suppressed by overexpression of yTAF12.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 2.
Schematic description of yTAF4 deletion
mutants. A, yeast TAF4 is schematically depicted.
Non-conserved regions are shown as a thin black
line, the linker region between the HFD and the CCTD as a
thick black line, the -helices of
the HFD are indicated as dark blue boxes, and the CCTD by a
light blue box. In yTAF4c1-3, the hTAF4 CCTD and/or 3
helices are differentiated from their yTAF4 counterparts by
coloring and in yTAF4c2 and c3 the hTAF4 linker region is
shown by an open box. The presence of substituted amino
acids is indicated with an asterisk. The amino acid
coordinates of the deletion end points, the HFD, and the CCTD are
indicated. The ability of each construct to complement the growth of
the taf4 strain when expressed from a high copy vector or
a low copy vector under the control of the TAF4 promoter is indicated
to the right. TS indicates temperature sensitive growth.
B, the location of amino acid substitutions within the HFD
and CCTD is indicated. The wild-type amino acid sequence is indicated
on the first line and the mutated residues are shown
below.
|
|
In plasmid shuffle experiments, full-length wild-type yTAF4 rescued the
growth of the taf4 null strain (Fig.
3A, sector 1, summarized in Fig. 2A), although no rescue was seen with the
expression vector alone (Fig. 3A, sector 2).
Growth was also seen when the non-conserved N-terminal region upstream
of the HFD was deleted (Fig. 3A, sector 4 and
Fig. 3B, sector 1; yTAF4 (186-388)). Similarly, deletion of the 1 helix and the 1 helix and loop L1 of the HFD did not abolish yTAF4 function (Fig. 3B, sectors
2 and 3; yTAF4 (203-388) and yTAF4 (213-388)), which
was lost upon additional deletion of the N-terminal half of the 2
helix (Fig. 3B, sector 4; yTAF4 (231-388), summarized in
Fig. 2A). In agreement with the observation that the 1
helix could be deleted without abolishing function, a mutation within
this helix also did not affect growth (Fig. 2B,
yTAF4m3 and Fig. 3A, sector 8). In
contrast, mutations in the 2 helix either completely abolished
function (Fig. 2B, yTAF4m1, m2 and
Fig. 3A, sectors 6 and 7) or led to a
TS phenotype (yTAF4m4, Fig. 3C, sector 1). Hence,
the central 2 helix of the HFD is critical for yTAF4 function.
Surprisingly however, mutation (yTAF4 (186-388)m6, Fig. 2,
A and B) or deletion (yTAF4 (251-261), Fig.
2A) of the 3 helix did not affect the ability to
efficiently complement (Fig. 3E, sectors 2 and
3, summarized in Fig. 2A).

View larger version (43K):
[in this window]
[in a new window]
|
Fig. 3.
Complementation of the taf4
strain. The growth of yeast plated at the indicated
temperatures is shown. The complementing plasmids used are indicated
alongside the plates. A-C show the results
obtained with the high copy vector, and D-F shows the low
copy vector. In panel F, serial 10-fold dilutions
are shown.
|
|
Although the above results show that yTAF4 HFD is required for
function, no complementation is seen with the construct yTAF4 (186-280) containing the HFD alone (Fig. 3A, sector
3), indicating that the linker region and/or the CCTD are also
required. Indeed, deletion of the CCTD completely abolished function
(Fig. 3A, sector 5; yTAF4 (1-356)). Mutation of
two highly conserved residues within the yTAF4 CCTD led to a TS
phenotype when introduced into the (186-388) deletion mutant (Fig.
3C, sector 2; mutation yTAF4 (186-388)m5). In
addition, deletion of the linker region between the presumed 3 helix
of the HFD and the CCTD led to a loss of function (yTAF4 (288-329),
summarized in Fig. 2A). Similarly, deletion of the entire
linker region and the presumed 3 helix (yTAF4 (251-358), Fig.
2A), which brings the CCTD into close proximity to the 2 helix (see also below), also led to a loss of function (Fig.
3E, sector 4). Interestingly, neither the hTAF4
CCTD alone, nor the combination of the hTAF4 CCTD and linker regions
can substitute for the equivalent yTAF4 regions and support yeast
growth (yTAF4c1 and yTAF4c2, Fig. 3B, sector 5 and Fig. 3E, sector 5). Finally, exchanging the
yTAF4 linker region by that of hTAF4 did not permit complementation
(yTAF4c3, Fig. 3E, sector 6).
Some of the above complementation results were performed with a high
copy expression vector containing the strong alcohol dehydrogenase promoter. To exclude the possibility that some of the derivatives may complement due to increased expression, those bearing deletion and point mutations for which complementation was
observed were also expressed under the control of the natural yTAF4
promoter sequence in a low copy vector (as described under "Experimental Procedures").
As observed above, wild-type yTAF4 and the (186-388) derivative
containing only the conserved regions both supported growth (Fig.
3D, sector 1 and 7). When expressed
from this vector, deletion or mutation of the 1 helix did not affect
complementation (summarized in Fig. 2A and 3F,
sector 3). However, deletion of the 1 helix and L1 loop
of the HFD led to impaired growth at 28 °C and a TS phenotype (Fig.
3D, sector 6 and Fig. 3F, sector
4). Similar to the high copy vector, complementation and a TS
phenotype were observed with yTAF4 (186-388)m5 (Fig. 3D,
sector 3 and Fig. 3F, sector 5). No TS
phenotype was, however, observed when the mutation was introduced in
the context of the full-length protein (Fig. 3F, yTAF4
(1-388)m5). The only significant difference with the low copy vector
was observed with yTAF4 (1-388)m4 containing a mutation in the 2
helix. When expressed from a high copy expression vector, this
derivative complemented at 28 °C and led to a TS phenotype
(summarized in Fig. 2A), whereas when expressed from the low
copy vector, no complementation was seen (Fig. 3D,
sectors 4 and 5).
Taken together, the above results show that the 2 helix of the HFD
is critical for function, but that the 1 helix is not absolutely
required. The CCTD and the intervening region are also essential
domains, because their deletion results in a loss of function even when
expressed from a high copy vector. Therefore, the evolutionarily
conserved regions of yTAF4 all contribute to function in
vivo.
Selective Genetic Interactions between the HFD and CCTD
of yTAF4 and yTAF12--
As shown above, we have isolated mutations in
the CCTD or in the HFD with a TS phenotype. We overexpressed the other
histone-like yTAFIIs in strains harboring each mutation in
order to test their ability to suppress this TS phenotype and hence to
interact genetically with yTAF4. With the strain harboring the yTAF4
(1-388)m4 mutation in the HFD, overexpression of wild-type yTAF4
efficiently rescued growth as expected (summarized in Fig.
4A). However, of the other yTAFIIs tested, only the expression of yTAF12 was able to
rescue the growth at the non-permissive temperature, whereas all
strains grew at the permissive temperature (summarized in Fig.
4A). A similar result was obtained using mutation yTAF4
(186-388)m5 in the CCTD (Fig. 4, A and B). These
results show strong and selective genetic interactions between yTAF12
and the HFD and CCTD of yTAF4.

View larger version (38K):
[in this window]
[in a new window]
|
Fig. 4.
High copy suppression of the yTAF4 m4 and m5
strains. A, the ability of the overexpressed
yTAFIIs shown on the left column of the table to suppress
the TS phenotype of the yTAF4 m4 or m5 (expressed from the high copy
vector) strains is summarized. B, the experimental result
for the high copy suppression of the yTAF4 m5 strain is shown. Yeast
were plated at the indicated temperatures, and the overexpression
plasmids used are indicated below the plates.
|
|
The CCTD Is Required for Heterodimerization of yTAF4 and
yTAF12--
Direct physical interactions between yTAF4 and yTAF12 have
previously been observed (30, 35), however, the domains of yTAF4
required for this have not been determined. To address this question,
yTAF4 deletion mutants were tested for their ability to heterodimerize
with a histidine-tagged derivative of the yTAF12 HFD when
coexpressed in E. coli, a powerful method for investigating heterodimerization of TAFIIs (33, 39). After coexpression, the bacterial extracts were separated on cobalt agarose beads, and the
retained proteins were analyzed by electrophoresis and staining with
Coomassie Brilliant Blue.
When coexpressed with the histidine-tagged yTAF12 (409-491), efficient
heterodimerization was observed with full-length wild-type yTAF4, which
was retained on the beads only in the presence of yTAF12 (Fig.
5B, lanes
2 and 3). As previously observed with other HFDs,
coexpression and heterodimerization also led to an increase in
solubility of the yTAF12 HFD (lanes 1 and 3).
Heterodimerization was also observed with yTAF4 (144-388) in which the
N-terminal region has been deleted (lane 5). In
contrast, only small amounts of heterodimer were seen with the
construct yTAF4 (144-280) in which the conserved C-terminal sequence
was deleted (lane 7). We also tested the ability of several
other constructs equivalent to those tested in the complementation
experiments for their ability to heterodimerize. Deletion of the linker
region between the presumed 3 helix and the CCTD resulted in
efficient production of the heterodimer (yTAF4 (144-388) 1,
lane 9), showing that this domain is not required
for heterodimerization. Moreover, a deletion of the presumed 3 helix
and linker region, leaving only a short loop region and bringing the
CCTD in close proximity to the 2 helix also resulted in highly
efficient heterodimer production (yTAF4 (144-388) 2, lane
11). These results show that deletion of the CCTD, but not
the linker region strongly impairs heterodimer production while
bringing the CCTD close to the 2 helix results in highly
efficient heterodimer production.

View larger version (28K):
[in this window]
[in a new window]
|
Fig. 5.
Direct heterodimerization of yTAF4 with
yTAF12. A, The expression plasmids used are depicted
schematically. The presence of a 6-histidine tag at the N terminus of
the yTAF12 derivatives is indicated. B and C,
after coexpression of the proteins indicated above each lane, the
bacterial extracts were separated over Co2+ agarose, and
the retained proteins were analyzed by SDS-PAGE and staining with
Coomassie Brilliant Blue. The positions of migration of the yTAF4 and
yTAF12 derivatives are indicated to the right and left of the figure or
with asterisks.
|
|
Heterodimerization with yTAF12 was strongly impaired by mutations m1,
m2, and m4 within the 2 helix of the yTAF4 HFD (Fig. 5C,
lanes 1-3). Similarly, mutation m5 in the CCTD and
replacement of the yTAF4 CCTD by that of hTAF4 (yTAF4 c1) also impaired
heterodimerization compared with that seen with the equivalent
wild-type construction (compare lanes 4,
5, and 6). This observation shows that the CCTD plays a direct role in heterodimerization with yTAF12.
Mutation of the yTAF4 HFD and CCTD Affects Gene
Expression--
Here we describe two novel TS mutants in yTAF4. To
determine the effect of each mutation on overall RNA polymerase II
transcription, the levels of poly(A)+ RNA were examined in
each strain following the shift to 37 °C. As a control in these
experiments, we included the previously characterized yTAF10 mutant
strain (G210E) bearing a mutation in the HFD. In this strain, bulk
poly(A)+ levels are strongly reduced (18). Total RNA was
prepared from each yeast strain grown at 28 °C, and after growth at
37 °C for between 15 min and 2 h, poly(A)+ levels
were quantified by hybridization with an oligo(dT) probe and PhosphorImaging.
As previously described, the level of poly(A)+ mRNA
fell off rapidly to less than 25% of the control value after shift of
the yTAF10(G210E) mutant strain to 37 °C (Fig.
6). Mutation of the CCTD also led to a
strong reduction in poly(A)+ mRNA levels, which
decreased to around 30% (Fig. 6). In contrast, the mutation in the
2 helix of the HFD had a less dramatic effect (Fig. 6). These
results show that the integrity of the CCTD is rather broadly required
for transcription.

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 6.
Bulk mRNA levels in the mutant
strains. A quantitative graphical representation of bulk
poly(A)+ levels in mutant strains is shown. The level of
poly(A)+ RNA in each strain measured at the time of shift
to 37 °C is taken as 100%. The relative levels of Poly(A)+ RNA
(vertical axis) measured at the times after shift to 37 °C on the
horizontal axis are shown for each mutant.
|
|
 |
DISCUSSION |
In this report, we show that the conserved region of yTAF4 is
required for yeast viability. We demonstrate that the CCTD of yTAF4
interacts genetically with yTAF12, is broadly required for transcription in vivo, and is required for optimal
heterodimerization with yTAF12 in vitro. Together with the
structure of the human TAF4-TAF12 heterodimer in the accompanying paper
(48), our results provide evidence that the HFD of the TAF4 family has
an unexpected organization where the 3 helix is located within the
CCTD.
Functional Domains of yTAF4--
We have previously proposed that
TAF4 contains a HFD that mediates heterodimerization with that of TAF12
(29). Analysis of yTAF4 shows that the HFD is essential for function
in vivo. Mutations in the 2 helix of the HFD
abolish function or lead to a TS phenotype. These mutations also impair
heterodimerization in in vitro coexpression experiments. In
parallel with our study, the x-ray crystal structure of the
hTAF4-hTAF12 histone-like pair was determined (48), indicating that
hTAF12 adopts a canonical histone fold and showing the presence of an
1-L1- 2 in hTAF4. From the structure, it can be seen that the
above mutations are indeed located within the heterodimerization
interface. The correlation with complementation indicates that
yTAF4-yTAF12 heterodimerization is essential for function in
vivo. It is, however, surprising that deletion or mutation of the
1 helix that contributes significantly to the heterodimerization
interface seen in the structure does not have a more radical effect.
In contrast to yTAF12, yTAF10, or yTAF3 (16-18, 33, 40), the
previously ascribed yTAF4 HFD is not by itself sufficient for growth,
which requires the entire conserved C-terminal region. Deletion of the
CCTD results in a loss of function. Impaired heterodimerization with
yTAF12 is also seen when the CCTD is deleted and with mutant m5 in the
CCTD which shows a TS phenotype in vivo. The yTAF4c1 in
which the yTAF4 CCTD is replaced by that of hTAF4 does not complement
in vivo and displays impaired heterodimerization. The hTAF4
and yTAF4 CCTDs are closely related but not identical. There are
several amino acid substitutions and an additional amino acid in the
human sequence. Any one or several of these evolutionary changes may
hinder heterodimerization and any other function(s) of the CCTD and
lead to a loss of the ability to complement.
In contrast to the above, deletion of the linker region does not affect
heterodimerization but abolishes function in vivo. Hence,
this loss of function cannot be ascribed to a loss of
heterodimerization with yTAF12 suggesting that the conserved linker
region plays a distinct role in vivo perhaps interacting
with other TFIID subunits or mediating interactions of TFIID with other
cellular proteins. As for the CCTD, species specificity is also
observed, as the hTAF4 linker region cannot substitute for the
equivalent region of yTAF4.
Mutation of the yTAF4 CCTD has a dramatic effect on bulk mRNA
levels upon shift to 37 °C, indicating that this domain is rather broadly required for transcription. This mutation is more detrimental than the m4 mutation in the yTAF4 HFD. However, it is important to note
that the m5 mutation is present in the context of a deletion of the
N-terminal region. In fact, the m5 mutation has an effect only in this
context, but not in the context of the full-length protein. The fact
that deletion of the N-terminal region alone has no effect suggests
that there is a sequence within the N-terminal region, perhaps an
additional N helix as found in histone H3 or hTAF11 (32), which
plays a partially redundant role with the CCTD and can suppress the
effect of mutation, but not deletion of the CCTD. Nevertheless, our
results suggest that distinct mutations within yTAF4 can have
differential effects on gene expression, a conclusion confirmed by
gene-specific effects of these yTAF4 mutations.2 The
conclusion that the full spectrum of activity of a given TAF cannot be
derived from the study of a single mutated allele has been underscored
by analysis of distinct mutations in yTAF10 or yTAF5, which have
dramatically different effects both on gene transcription and
cell-cycle progression (40-42).
An Unexpected Organization of the yTAF4 HFD--
A mutation in the
yTAF4 2 helix (M219P) leads to a TS phenotype. The introduction of
proline residues in the 2 helix of several other yTAFIIs
has also previously been shown to generate TS phenotypes and has proven
useful for examining genetic interactions in yeast (15, 33). Using the
TS mutation in the yTAF4 2 helix, we find a strong and selective
genetic interaction with yTAF12, whose overexpression rescues the
growth at restrictive temperature. These results are complementary to
those of Reese et al. (35), who have shown that
overexpression of yTAF4 could rescue the TS phenotype of a yTAF12 TS
mutant containing a partial deletion of the 3 helix. Hence, there is
a reciprocal genetic interaction in vivo between the HFDs of
yTAF4 and yTAF12, suggesting that this pair exists within the native
TFIID. The existence of this pair in vivo is also supported
by the colocalization of yTAF4 and yTAF12 observed in immunoelectron
microscopy within native yeast TFIID (31).
Our results extend those cited above by demonstrating a further
selective genetic interaction between yTAF12 and the yTAF4 CCTD. While
this work was in progress, Selleck et al. (30) reported that
a TS mutation in the HFD of yTAF4 could be suppressed by overexpression
of yTAF12. A reevaluation of this observation (43) indicates that the
mutation conferring temperature sensitivity to this yTAF4 derivative is
L365P, which does not lie within the presumed HFD region, but within
the CCTD (see Fig. 1B). This observation provides
independent corroboration of a genetic interaction between yTAF12 and
the yTAF4 CCTD.
Given this strong genetic interaction, it was not surprising to find
that yTAF4 directly heterodimerizes with yTAF12 when coexpressed in
E. coli. These results extend those of Reese et al. (35),who showed an interaction between yTAF4 and yTAF12 in glutathione S-transferase-pulldown experiments. Selleck
et al. (30) have reported heterodimerization of full-length
yTAF4 and an N-terminally deleted derivative of yTAF12 upon
coexpression in E. coli. Here we show that
heterodimerization requires only the yTAF12 HFD, but that for yTAF4 the
CCTD is additionally required. Full-length yTAF4 or only the conserved
region heterodimerize efficiently with the HFD of yTAF12. In contrast,
with only the yTAF4 HFD greatly reduced production of the heterodimer
was obtained. Mutations in the CCTD impaired heterodimerization,
whereas deletion of the presumed 3 helix as well as the linker
region did not impair heterodimer production, but rather led to an
optimal yield. Hence, when the CCTD is deleted or mutated, but not when
the intervening linker region including the putative 3 helix is
deleted, a reduction in heterodimer production is observed. This
observation is in agreement with genetic suppressor results in
vivo and shows that the CCTD directly contributes to efficient
heterodimerization with yTAF12.
With the determination of the hTAF4-hTAF12 structure, it was noted that
the amino acids encoding the presumed hTAF4 3 helix were present
within the crystal, but were disorganized, suggesting that this region
probably does not correspond to the 3 helix. Therefore, either hTAF4
belongs to a novel class of HFD which does not contain an 3 helix or
an 3 helix is located elsewhere within the C-terminal domain.
Several observations made during the analysis of yTAF4 suggest that an
3 helix is located within the CCTD. The CCTD is highly conserved in
the TAF4 family. Within the CCTD, a region of strong similarity to
other experimentally determined HFD 3 helices can be observed with a
conserved D(L/V/M/I) pair (Fig. 1B). This Asp residue, which is mutated in our m5 derivative plays an important role
in several HFDs by forming an intramolecular bond with an arginine
residue in the L2 loop, whereas the L365P mutation described by Selleck
et al. (30) is located immediately following the DL pair
(see asterisks in Fig. 1B). Hence, the mutations
conferring a TS phenotype and impairing heterodimerization lie within a
region showing high sequence similarity to known 3 helices (Fig.
1B). The suppression of these mutations upon overexpression
of yTAF12 and the impaired heterodimerization seen in vitro
provides strong evidence that this is indeed the 3 helix of the TAF4
HFD. In contrast, deletion or mutation of the previously
ascribed 3 helix has no effect on yTAF4 function in
vivo and does not affect heterodimerization in vitro.
Together, these observations point to the possible presence of an 3
helix within the CCTD, showing that the TAF4 HFD has an unexpected
organization with an extended linker between the 2 and 3 helices.
The presence of an extended L2 loop within the HFD of yTAF10 and yTAF11
has previously been noted (30, 33, 40). However, in contrast to yTAF4,
these loops are not present in the metazoan orthologues and can be
deleted in the yeast proteins without loss of function. In the TAF4
family, the extended loop region is conserved and cannot be deleted
without loss of function. Hence, the yTAF4 HFD has a novel organization
in which a functional domain is located within the L2 loop.
In addition to mediating heterodimerization with TAF12, the conserved
region of TAF4 also mediates interaction with the Q-rich region of the
cAMP-response element-binding protein transcriptional activator
(44). It has been suggested that proteins harboring poly(Q) expansions
interact with the conserved region of TAF4 and provoke the development
of neurodegenerative diseases by sequestration of TAF4 and interference
with cAMP-response element-binding protein function (45). Moreover,
TAF4 interacts with the adenovirus E1A protein, and this interaction
absolutely requires the CCTD (46). Finally, the TAF4 linker and CCTD
regions interact with the general transcription factor TFIIA (47).
Given this plethora of interactions, it is not surprising that the
conserved region of TAF4 has a complex organization and contains
several functional elements.
 |
ACKNOWLEDGEMENTS |
We thank L. Carré for excellent
technical assistance, S. Vicaire and D. Stephane for DNA sequencing,
the staff of the oligonucleotide facilities, and B. Boulay for help
with illustrations.
 |
FOOTNOTES |
*
This work was partially supported by grants from CNRS,
INSERM, the Hôpital Universitaire de Strasbourg, the
Ministère de la Recherche et de la Technologie, the Association
pour la Recherche contre le Cancer, the Ligue Nationale contre le
Cancer, National Institutes of Health Grant GM52461 (to P. A. W.) and
the Human Frontier Science Program Research Grant RG0196 (to I. D. and
P. A. W.).The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by a fellowship from the Région Alsace.
¶
Supported by a fellowship from the Ligue National Contre le Cancer.
Present address: The Friedrich Miescher Institute,
Maulbeerstrasse 66, P.O. Box 2543, CH-4002 Basel, Switzerland.

To whom correspondence should be addressed. Tel.:
33-3-88-65-34-40-45; Fax: 33-3-88-65-32-01; E-mail:
irwin@titus.u-strasbg.fr.
Published, JBC Papers in Press, September 16, 2002, DOI 10.1074/jbc.M206556200
2
S. T. and I. D., manuscript in preparation.
 |
ABBREVIATIONS |
The abbreviations used are:
TBP, TATA-binding
protein;
TAFII, TBP-associated factor;
HFD, histone-fold
domain;
TS, temperature sensitive;
CCTD, conserved C-terminal domain;
y, yeast;
h, human.
 |
REFERENCES |
| 1.
|
Hampsey, M.
(1998)
Microbiol. Mol. Biol. Rev.
62,
465-503[Abstract/Free Full Text]
|
| 2.
|
Bell, B.,
and Tora, L.
(1999)
Exp. Cell Res.
246,
11-19[CrossRef][Medline]
[Order article via Infotrieve]
|
| 3.
|
Gangloff, Y.,
Romier, C.,
Thuault, S.,
Werten, S.,
and Davidson, I.
(2001)
Trends Biochem. Sci.
26,
250-257[CrossRef][Medline]
[Order article via Infotrieve]
|
| 4.
|
Wieczorek, E.,
Brand, M.,
Jacq, X.,
and Tora, L.
(1998)
Nature
393,
187-191[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Brand, M.,
Yamamoto, K.,
Staub, A.,
and Tora, L.
(1999)
J. Biol. Chem.
274,
18285-18289[Abstract/Free Full Text]
|
| 6.
|
Grant, P. A.,
Schieltz, D.,
Pray-Grant, M. G.,
Steger, D. J.,
Reese, J. C.,
Yates, J. R.,
and Workman, J. L.
(1998)
Cell
94,
45-53[CrossRef][Medline]
[Order article via Infotrieve]
|
| 7.
|
Ogryzko, V. V.,
Kotani, T.,
Zhang, X.,
Schlitz, R. L.,
Howard, T.,
Yang, X. J.,
Howard, B. H.,
Qin, J.,
and Nakatani, Y.
(1998)
Cell
94,
35-44[CrossRef][Medline]
[Order article via Infotrieve]
|
| 8.
|
Martinez, E.,
Kundu, T. K., Fu, J.,
and Roeder, R. G.
(1998)
J. Biol. Chem.
273,
23781-23785[Abstract/Free Full Text]
|
| 9.
|
Saurin, A. J.,
Shao, Z.,
Erdjument-Bromage, H.,
Tempst, P.,
and Kingston, R. E.
(2001)
Nature
412,
655-660[CrossRef][Medline]
[Order article via Infotrieve]
|
| 10.
|
Green, M. R.
(2000)
Trends Biochem. Sci
25,
59-63[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Walker, S. S.,
Reese, J. C.,
Apone, L. M.,
and Green, M. R.
(1996)
Nature
383,
185-188[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Apone, L. M.,
Virbasius, C. M.,
Reese, J. C.,
and Green, M. R.
(1996)
Genes Dev.
10,
2368-2380[Abstract/Free Full Text]
|
| 13.
|
Apone, L. M.,
Virbasius, C. A.,
Holstege, F. C.,
Wang, J.,
Young, R. A.,
and Green, M. R.
(1998)
Mol. Cell
2,
653-661[CrossRef][Medline]
[Order article via Infotrieve]
|
| 14.
|
Komarnitsky, P. B.,
Michel, B.,
and Buratowski, S.
(1999)
Genes Dev.
13,
2484-2489[Abstract/Free Full Text]
|
| 15.
|
Michel, B.,
Komarnitsky, P.,
and Buratowski, S.
(1998)
Mol. Cell
2,
663-673[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Moqtaderi, Z.,
Keaveney, M.,
and Struhl, K.
(1998)
Mol. Cell
2,
675-682[CrossRef][Medline]
[Order article via Infotrieve]
|
| 17.
|
Natarajan, K.,
Jackson, B. M.,
Rhee, E.,
and Hinnebusch, A. G.
(1998)
Mol. Cell
2,
683-692[CrossRef][Medline]
[Order article via Infotrieve]
|
| 18.
|
Sanders, S. L.,
Klebanow, E. R.,
and Weil, P. A.
(1999)
J. Biol. Chem.
274,
18847-18850[Abstract/Free Full Text]
|
| 19.
|
Soldatov, A.,
Nabirochkina, E.,
Georgieva, S.,
Belenkaja, T.,
and Georgiev, P.
(1999)
Mol. Cell. Biol.
19,
3769-3778[Abstract/Free Full Text]
|
| 20.
|
Zhou, J.,
Zwicker, J.,
Szymanski, P.,
Levine, M.,
and Tjian, R.
(1998)
Proc. Natl. Acad. Sci. U. S. A.
95,
13483-13488[Abstract/Free Full Text]
|
| 21.
|
Hernandez-Hernandez, A.,
and Ferrus, A.
(2001)
Mol. Cell. Biol.
21,
614-623[Abstract/Free Full Text]
|
| 22.
|
Wassarman, D. A.,
Aoyagi, N.,
Pile, L. A.,
and Schlag, E. M.
(2000)
Proc. Natl. Acad. Sci. U. S. A.
97,
1154-1159[Abstract/Free Full Text]
|
| 23.
|
Metzger, D.,
Scheer, E.,
Soldatov, A.,
and Tora, L.
(1999)
EMBO J.
18,
4823-4834[CrossRef][Medline]
[Order article via Infotrieve]
|
| 24.
|
Chen, Z.,
and Manley, J. L.
(2000)
Mol. Cell. Biol.
20,
5064-5076[Abstract/Free Full Text]
|
| 25.
|
Sekiguchi, T.,
Nohiro, Y.,
Nakamura, Y.,
Hisamoto, N.,
and Nishimoto, T.
(1991)
Mol. Cell. Biol.
11,
3317-3325[Abstract/Free Full Text]
|
| 26.
| Perletti, L., Kopf, E., Carre, L., and Davidson, I. (2001) BMC
Mol. Biol. 2, www.biomedcentral.com/1471-2199/2/4
|
| 27.
|
Xie, X.,
Kokubo, T.,
Cohen, S. L.,
Mirza, U. A.,
Hoffmann, A.,
Chait, B. T.,
Roeder, R. G.,
Nakatani, Y.,
and Burley, S. K.
(1996)
Nature
380,
316-322[CrossRef][Medline]
[Order article via Infotrieve]
|
| 28.
|
Hoffmann, A.,
Chiang, C. M.,
Oelgeschlager, T.,
Xie, X.,
Burley, S. K.,
Nakatani, Y.,
and Roeder, R. G.
(1996)
Nature
380,
356-359[CrossRef][Medline]
[Order article via Infotrieve]
|
| 29.
|
Gangloff, Y. G.,
Werten, S.,
Romier, C.,
Carre, L.,
Poch, O.,
Moras, D.,
and Davidson, I.
(2000)
Mol. Cell. Biol.
20,
340-351[Abstract/Free Full Text]
|
| 30.
|
Selleck, W.,
Howley, R.,
Fang, Q.,
Podolny, V.,
Fried, M. G.,
Buratowski, S.,
and Tan, S.
(2001)
Nat. Struct. Biol.
8,
695-700[CrossRef][Medline]
[Order article via Infotrieve]
|
| 31.
|
Leurent, C.,
Sanders, S.,
Ruhlman, C.,
Mallouh, V.,
Weil, P. A.,
Kirschner, D. B.,
Tora, L.,
and Schultz, P.
(2002)
EMBO J.
21,
3424-3433[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Birck, C.,
Poch, O.,
Romier, C.,
Ruff, M.,
Mengus, G.,
Lavigne, A. C.,
Davidson, I.,
and Moras, D.
(1998)
Cell
94,
239-249[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Gangloff, Y. G.,
Sanders, S. L.,
Romier, C.,
Kirschner, D.,
Weil, P. A.,
Tora, L.,
and Davidson, I.
(2001)
Mol. Cell. Biol.
21,
1841-1853[Abstract/Free Full Text]
|
| 34.
|
Gangloff, Y. G.,
Pointud, J. C.,
Thuault, S.,
Carre, L.,
Romier, C.,
Muratoglu, S.,
Brand, M.,
Tora, L.,
Couderc, J. L.,
and Davidson, I.
(2001)
Mol. Cell. Biol.
21,
5109-5121[Abstract/Free Full Text]
|
| 35.
|
Reese, J. C.,
Zhang, Z.,
and Kurpad, H.
(2000)
J. Biol. Chem.
275,
17391-17398[Abstract/Free Full Text]
|
| 36.
|
Sanders, S. L.,
and Weil, P. A.
(2000)
J. Biol. Chem.
275,
13895-13900[Abstract/Free Full Text]
|
| 37.
|
Mumberg, D.,
Muller, R.,
and Funk, M.
(1995)
Gene
156,
119-122[CrossRef][Medline]
[Order article via Infotrieve]
|
| 38.
|
Schroeder, S. C.,
and Weil, P. A.
(1998)
Nucleic Acids Res.
26,
4186-4195[Abstract/Free Full Text]
|
| 39.
|
Fribourg, S.,
Romier, C.,
Werten, S.,
Gangloff, Y. G.,
Poterszman, A.,
and Moras, D.
(2001)
J. Mol. Biol.
306,
363-373[CrossRef][Medline]
[Order article via Infotrieve]
|
| 40.
|
Kirschner, D.,
Saunders, SL.,
Vom Bauer, E.,
Gangloff, Y-G.,
Davidson, I.,
Weil, P. A.,
and Tora, L.
(2001)
Mol. Cel. Biol.
22,
3178-3193
|
| 41.
|
Kirchner, J.,
Sanders, S. L.,
Klebanow, E.,
and Weil, P. A.
(2001)
Mol. Cell. Biol.
21,
6668-6680[Abstract/Free Full Text]
|
| 42.
|
Durso, R. J.,
Fisher, A. K.,
Albright-Frey, T. J.,
and Reese, J. C.
(2001)
Mol. Cell. Biol.
21,
7331-7344[Abstract/Free Full Text]
|
| 43.
|
Selleck, W.,
Howley, R.,
Fang, Q.,
Podolny, V.,
Fried, M.,
Buratowski, S.,
and Tan, S.
(2002)
Nat. Struct. Biol.
9,
231[CrossRef]
|
| 44.
|
Asahara, H.,
Santoso, B.,
Guzman, E., Du, K.,
Cole, P. A.,
Davidson, I.,
and Montminy, M.
(2001)
Mol. Cell. Biol.
21,
7892-7900[Abstract/Free Full Text]
|
| 45.
|
Shimohata, T.,
Nakajima, T.,
Yamada, M.,
Uchida, C.,
Onodera, O.,
Naruse, S.,
Kimura, T.,
Koide, R.,
Nozaki, K.,
Sano, Y.,
Ishiguro, H.,
Sakoe, K.,
Ooshima, T.,
Sato, A.,
Ikeuchi, T.,
Oyake, M.,
Sato, T.,
Aoyagi, Y.,
Hozumi, I.,
Nagatsu, T.,
Takiyama, Y.,
Nishizawa, M.,
Goto, J.,
Kanazawa, I.,
Davidson, I.,
and Tanese, N.
(2000)
Nat. Genet.
26,
29-36[CrossRef][Medline]
[Order article via Infotrieve]
|
| 46.
|
Mazzarelli, J. M.,
Mengus, G.,
Davidson, I.,
and Ricciardi, R. P.
(1997)
J. Virol.
71,
7978-7983[Abstract]
|
| 47.
|
Guermah, M.,
Tao, Y.,
and Roeder, R. G.
(2001)
Mol. Cell. Biol.
21,
6882-6894[Abstract/Free Full Text]
|
| 48.
|
Werten, S.,
Mitschler, A.,
Romier, C.,
Gangloff, Y.-G.,
Thuault, S.,
Davidson, I.,
and Moras, D.
(2002)
J. Biol. Chem.
277,
45502-45509[Abstract/Free Full Text]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
A. Fadloun, D. Kobi, J.-C. Pointud, A. K. Indra, M. Teletin, C. Bole-Feysot, B. Testoni, R. Mantovani, D. Metzger, G. Mengus, et al.
The TFIID subunit TAF4 regulates keratinocyte proliferation and has cell-autonomous and non-cell-autonomous tumour suppressor activity in mouse epidermis
Development,
August 15, 2007;
134(16):
2947 - 2958.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. A. Garbett, M. K. Tripathi, B. Cencki, J. H. Layer, and P. A. Weil
Yeast TFIID Serves as a Coactivator for Rap1p by Direct Protein-Protein Interaction
Mol. Cell. Biol.,
January 1, 2007;
27(1):
297 - 311.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Shao, M. Revach, S. Moshonov, Y. Tzuman, K. Gazit, S. Albeck, T. Unger, and R. Dikstein
Core Promoter Binding by Histone-Like TAF Complexes
Mol. Cell. Biol.,
January 1, 2005;
25(1):
206 - 219.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Hiller, X. Chen, M. J. Pringle, M. Suchorolski, Y. Sancak, S. Viswanathan, B. Bolival, T.-Y. Lin, S. Marino, and M. T. Fuller
Testis-specific TAF homologs collaborate to control a tissue-specific transcription program
Development,
November 1, 2004;
131(21):
5297 - 5308.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Chen and J. L. Manley
In Vivo Functional Analysis of the Histone 3-like TAF9 and a TAF9-related Factor, TAF9L
J. Biol. Chem.,
September 12, 2003;
278(37):
35172 - 35183.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Werten, A. Mitschler, C. Romier, Y.-G. Gangloff, S. Thuault, I. Davidson, and D. Moras
Crystal Structure of a Subcomplex of Human Transcription Factor TFIID Formed by TATA Binding Protein-associated Factors hTAF4 (hTAFII135) and hTAF12 (hTAFII20)
J. Biol. Chem.,
November 15, 2002;
277(47):
45502 - 45509.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|